Alpha 2.0
Login Register
» Authors » Willem Dewilde

Willem Dewilde

Explore the profile of Willem Dewilde including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 142
Followers 0
Related Specialties
Cardiology & Vascular Diseases
Radiology
Pharmacology
Top 10 Co-Authors
Paul Dendale
Alain Nchimi
Olivier Ghekiere
Stephan Windecker
Jurrien Ten Berg
Jurrien M Ten Berg
Pascal Vranckx
Walter Desmet
Andrea Rubboli
Adel Aminian
Published In
Int J Cardiol
Am Heart J
EuroIntervention
Am J Cardiol
Int J Cardiovasc Imaging
Affiliations
Soon will be listed here.
Recent Articles
1.
Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: Rationale and design of the COL BE PCI trial
De Cock E, Kautbally S, Timmermans F, Bogaerts K, Hanet C, Desmet W, et al.
Am Heart J . 2024 Sep; 278:61-71. PMID: 39233210
Introduction: Patients with coronary artery disease (CAD) remain vulnerable to future major atherosclerotic events after revascularization, despite effective secondary prevention strategies. Inflammation plays a central role in the pathogenesis of...
2.
Complete versus incomplete revascularization in patients with a non-ST-elevation myocardial infarction: Analysis from the e-ULTIMASTER registry
Jimenez Diaz V, Routledge H, Malik F, Hildick-Smith D, Guedes A, Baello P, et al.
Cardiovasc Revasc Med . 2024 Jul; PMID: 39079857
Background: Incomplete revascularization (ICR) has been associated with a worse prognosis after a percutaneous coronary intervention (PCI). In NSTEMI patients with multivessel disease (MVD) however, the benefit of a complete...
3.
Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial
Verburg A, Bor W, Kucuk I, Henriques J, Vink M, Ruifrok W, et al.
EuroIntervention . 2024 Jul; 20(14):e898-e904. PMID: 39007830
The optimal antithrombotic management of atrial fibrillation (AF) patients who require oral anticoagulation (OAC) undergoing percutaneous coronary intervention (PCI) remains unclear. Current guidelines recommend dual antithrombotic therapy (DAT; OAC plus...
4.
Impact of the number of modifiable risk factors on clinical outcomes after percutaneous coronary intervention: An analysis from the e-Ultimaster registry
Kobo O, Levi Y, Abu-Fanne R, von Birgelen C, Guedes A, Aminian A, et al.
Int J Cardiol Heart Vasc . 2024 Apr; 51:101370. PMID: 38628296
Aims: A substantial proportion of the patients undergoing percutaneous coronary intervention (PCI) have none of the of standard modifiable cardiovascular risk factors (SMuRFs): hypertension, diabetes, hypercholesterolaemia and smoking. The aim...
5.
Bleeding and thrombotic risk of different antiplatelet regimens posttranscatheter edge-to-edge mitral valve repair in patients with an indication for oral anticoagulation: Results from an all-comers national registry
Claeys M, Aminian A, Bartunek J, Bennett J, Buysschaert I, Claeys M, et al.
Catheter Cardiovasc Interv . 2023 Dec; 103(2):382-388. PMID: 38078877
Background: Evidence-based recommendations for antithrombotic treatment in patients who have an indication for oral anticoagulation (OAC) after transcatheter edge-to-edge mitral valve repair (TEER) are lacking. Aims: To compare bleeding and...
6.
Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients: Rationale and design of the LEGACY study
van der Sangen N, Kucuk I, Sivanesan S, Appelman Y, Ten Berg J, Verburg A, et al.
Am Heart J . 2023 Jul; 265:114-120. PMID: 37517430
Background: Early aspirin withdrawal, also known as P2Y-inhibitor monotherapy, following percutaneous coronary intervention (PCI) for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) can reduce bleeding without a trade-off in efficacy. Still...
7.
Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk
Smits P, Frigoli E, Vranckx P, Ozaki Y, Morice M, Chevalier B, et al.
J Am Coll Cardiol . 2022 Sep; 80(13):1220-1237. PMID: 36137672
Background: The optimal duration of antiplatelet therapy (APT) after coronary stenting in patients at high bleeding risk (HBR) presenting with an acute coronary syndrome remains unclear. Objectives: The objective of...
8.
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy
Valgimigli M, Frigoli E, Vranckx P, Ozaki Y, Morice M, Chevalier B, et al.
J Am Coll Cardiol . 2022 Aug; 80(8):766-778. PMID: 35981821
Background: Nonadherence to antiplatelet therapy after percutaneous coronary intervention (PCI) is common, even in clinical trials. Objectives: The purpose of this study was to investigate the impact of nonadherence to...
9.
Semi-Quantitative Versus Visual Analysis of Adenosine Perfusion Magnetic Resonance Imaging in Intermediate-Grade Coronary Artery Stenosis Using Fractional Flow Reserve as the Reference: A Pilot Study
Ghekiere O, Dacher J, Dewilde W, Cools W, Dendale P, Nchimi A
J Belg Soc Radiol . 2022 Jul; 106(1):59. PMID: 35814277
Background: To evaluate the diagnostic accuracy of semi-quantitative adenosine perfusion magnetic resonance imaging (MRI) to determine fractional flow reserve (FFR) ≤ 0.80 intermediate-grade coronary stenoses as compared to visual analysis....
10.
Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients
Claassens D, Gimbel M, Bergmeijer T, Vos G, Hermanides R, van der Harst P, et al.
Int J Cardiol . 2021 Apr; 334:10-17. PMID: 33887342
Background: Patients with acute coronary syndrome (ACS) who are carrying CYP2C19 loss-of-function alleles derive less benefit from clopidogrel treatment. Despite this, in elderly patients, clopidogrel might be preferred over more...